Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
Glioblastoma
Regorafenib
Thyroid
fT3/fT4
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
19
04
2023
accepted:
25
05
2023
medline:
7
7
2023
pubmed:
2
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Regorafenib demonstrated encouraging results in recurrent glioblastoma patients. Some studies showed that changes in circulating thyroid hormones (fT3, fT4, fT3/fT4 ratio) can be considered as prognostic factors in patients with various types of tumors. We designed this study to investigate the relationship between baseline thyroid variables and outcome in IDH-wild type GBM patients who were treated with regorafenib. This multicenter retrospective study included recurrent IDH-wild-type glioblastoma patients treated with regorafenib. Only patients with baseline thyroid function values (TSH, fT3, fT4, fT3/fT4 ratio) available were evaluated. RANO criteria were used to analyze neuroradiological response. Survival curves were estimated using the Kaplan-Meier method. The relationships between baseline thyroid variables (TSH, fT3, fT4, fT3/fT4) and survival (PFS, OS) were investigated with Cox regression models. From November 2015 to April 2022, 134 recurrent IDH-wildtype GBM patients were treated with regorafenib and 128 of these had information on baseline thyroid function value. Median follow-up was 8 months (IQR 4.7-14.0). Objective Response Rate was 9% and Disease Control Rate was 40.9%. Median PFS was 2.7 months (95%CI 2.2-3.6) and median OS was 10.0 months (95%CI 7.0-13.0). Lower baseline TSH value in the blood was correlated with a higher rate of disease progression to regorafenib (p = 0.04). Multivariable analyses suggested a non-linear relationship between PFS (p = 0.01) and OS (p = 0.03) with baseline fT3/fT4 ratio. In recurrent wild-type IDH glioblastoma patients, baseline fT3/fT4 ratio showed a non-linear relationship with survival, with different impacts across the spectrum of fT3/fT4 ratio. Moreover, baseline TSH may be a predictor of regorafenib activity.
Identifiants
pubmed: 37264256
doi: 10.1007/s11060-023-04356-w
pii: 10.1007/s11060-023-04356-w
pmc: PMC10322943
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
regorafenib
24T2A1DOYB
Thyrotropin
9002-71-5
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-383Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Ostrom QT, Price M, Neff C et al (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 24:v1–v95. https://doi.org/10.1093/neuonc/noac202
doi: 10.1093/neuonc/noac202
pubmed: 36196752
Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996.
Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255. https://doi.org/10.1002/ijc.25864
doi: 10.1002/ijc.25864
pubmed: 21170960
Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302. https://doi.org/10.1016/S0140-6736(12)61857-1
doi: 10.1016/S0140-6736(12)61857-1
pubmed: 23177515
Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X
doi: 10.1016/S0140-6736(12)61900-X
pubmed: 23177514
Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56–66. https://doi.org/10.1016/S0140-6736(16)32453-9
doi: 10.1016/S0140-6736(16)32453-9
pubmed: 27932229
Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110–119
doi: 10.1016/S1470-2045(18)30675-2
pubmed: 30522967
Pasqualetti G, Calsolaro V, Bernardini S et al (2018) Degree of peripheral thyroxin deiodination, frailty, and long-term survival in hospitalized older patients. J Clin Endocrinol Metab 103:1867–1876. https://doi.org/10.1210/jc.2017-02149
doi: 10.1210/jc.2017-02149
pubmed: 29546287
Lamprou V, Varvarousis D, Polytarchou K et al (2017) The role of thyroid hormones in acute coronary syndromes: prognostic value of alterations in thyroid hormones. Clin Cardiol 40:528–533. https://doi.org/10.1002/clc.22689
doi: 10.1002/clc.22689
pubmed: 28295435
pmcid: 6490650
De Alfieri W, Nistico F, Borgogni T et al (2013) Thyroid hormones as predictors of short- and long-term mortality in very old hospitalized patients. J Gerontol A Biol Sci Med Sci 68:1122–1128. https://doi.org/10.1093/gerona/glt012
doi: 10.1093/gerona/glt012
pubmed: 23459207
Fragidis S, Sombolos K, Thodis E et al (2015) Low T3 syndrome and long-term mortality in chronic hemodialysis patients. World J Nephrol 4:415–422. https://doi.org/10.5527/wjn.v4.i3.415
doi: 10.5527/wjn.v4.i3.415
pubmed: 26167466
pmcid: 4491933
Pinter M, Haupt L, Hucke F et al (2017) The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS ONE 12:e0181878. https://doi.org/10.1371/journal.pone.0181878
doi: 10.1371/journal.pone.0181878
pubmed: 28771610
pmcid: 5542594
Yasar ZA, Kirakli C, Yilmaz U et al (2014) Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study. HORM CANC 5:240–246. https://doi.org/10.1007/s12672-014-0183-0
doi: 10.1007/s12672-014-0183-0
Gao R, Liang J-H, Wang L et al (2017) Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma. Br J Haematol 177:95–105. https://doi.org/10.1111/bjh.14528
doi: 10.1111/bjh.14528
pubmed: 28146267
Schirripa M, Pasqualetti G, Giampieri R et al (2018) Prognostic value of thyroid hormone ratios in patients with advanced metastatic colorectal cancer treated with regorafenib: the TOREADOR study. Clin Colorectal Cancer 17:e601–e615. https://doi.org/10.1016/j.clcc.2018.05.013
doi: 10.1016/j.clcc.2018.05.013
pubmed: 30149875
Pasqualetti G, Schirripa M, Dochy E et al (2020) Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: results from the phase III randomised CORRECT trial. Eur J Cancer 133:66–73. https://doi.org/10.1016/j.ejca.2020.04.023
doi: 10.1016/j.ejca.2020.04.023
pubmed: 32446145
Maruzzo M, Verzoni E, Vitale MG et al (2021) Prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: results from the threefour study (Meet-URO 14). Front Oncol 11:787835. https://doi.org/10.3389/fonc.2021.787835
R Core Team (2022) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ .
Warner MH, Beckett GJ (2010) Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 205:1–13. https://doi.org/10.1677/JOE-09-0412
doi: 10.1677/JOE-09-0412
pubmed: 20016054
Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR (1991) Thyroid function after treatment of brain tumors in children. J Pediatr 119:733–737. https://doi.org/10.1016/s0022-3476(05)80288-4
doi: 10.1016/s0022-3476(05)80288-4
pubmed: 1941379
Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK et al (2003) A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. J Clin Endocrinol Metab 88:136–140. https://doi.org/10.1210/jc.2002-020380
doi: 10.1210/jc.2002-020380
pubmed: 12519842
Cosnarovici MM, Piciu A, Bonci E-A, et al (2020) Post-treatment thyroid diseases in children with brain tumors: a single-center experience at “Prof. Dr. Ion Chiricuță” Institute of Oncology, Cluj-Napoca. Diagnostics (Basel) 10:142. https://doi.org/10.3390/diagnostics10030142
Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM et al (2011) Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 96:2330–2340. https://doi.org/10.1210/jc.2011-0306
doi: 10.1210/jc.2011-0306
pubmed: 21613351
pmcid: 3146793
Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547. https://doi.org/10.1200/JCO.2012.45.2722
doi: 10.1200/JCO.2012.45.2722
pubmed: 23530101
Shang Y, Kuang M, Wang Z et al (2020) An ultrashort peptide-based supramolecular hydrogel mimicking IGF-1 to alleviate glucocorticoid-induced sarcopenia. ACS Appl Mater Interfaces 12:34678–34688. https://doi.org/10.1021/acsami.0c09973
doi: 10.1021/acsami.0c09973
pubmed: 32668906
Kaasik P, Umnova M, Pehme A et al (2007) Ageing and dexamethasone associated sarcopenia: peculiarities of regeneration. J Steroid Biochem Mol Biol 105:85–90. https://doi.org/10.1016/j.jsbmb.2006.11.024
doi: 10.1016/j.jsbmb.2006.11.024
pubmed: 17587565